Major Ingredients

Each Capsule Contains Salmeterol 50mcg as Salmeterol Xinafoate BP and Fluticasone Propionate BP 250mcg inhalation powder.

Major Functionality

Treatment of asthma : Fluticasone Propionate & Salmeterol Xinafoate combination is indicated for the treatment of asthma in patients aged 4 years and older. It is indicated for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. It is not indicated for the relief of acute bronchospasm.

Manufacture Information

Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.